T-knife Therapeutics Receives European Authorization for First-in-Human Trial of CRISPR-Edited T Cell Therapy TK-6302
核心洞察
T-knife Therapeutics (搜索) has received European authorization to initiate ATLAS, a Phase 1 trial of TK-6302 (搜索), a multi-armored CRISPR-edited T cell therapy targeting PRAME (搜索)-positive solid tumors (搜索).
TK-6302 (搜索) incorporates three engineering features to overcome solid tumor challenges: a high-affinity PRAME (搜索) receptor, a CD8 (搜索) co-receptor for enhanced T cell fitness, and a FAS (搜索)-based checkpoint converter.
The therapy targets PRAME (搜索), which is highly prevalent across multiple solid tumor types including squamous non-small cell lung, ovarian, endometrial, skin, and triple-negative breast cancers.
T-knife Therapeutics (搜索) has received European authorization of its Clinical Trial Application to initiate ATLAS, an adaptive, first-in-human, open-label Phase 1 study of TK-6302 (搜索) in patients with advanced PRAME (搜索)-positive solid tumors (搜索). The authorization enables the company to begin dosing patients in Europe this year, marking its transition to becoming a clinical-stage company.
Multi-Armored CRISPR Engineering Approach
TK-6302 (搜索) represents a multi-armored, CRISPR-edited T cell therapy specifically engineered to overcome the challenges associated with treating solid tumor cancers. The therapy incorporates three distinct engineering features designed to address solid tumor obstacles:
- A high-affinity PRAME-specific receptor to boost cytotoxicity
- A CD8 co-receptor to functionally engage CD4 T cells and support fitness and persistence
- A FAS-based checkpoint converter designed to counter pro-apoptotic signaling in the tumor microenvironment
The product is manufactured via a non-viral gene-editing process intended to optimize TCR expression and has been scaled on the company's clinical process.
Preclinical Efficacy Data
Preclinical work demonstrated TK-6302 (搜索)'s sustained serial killing and cytokine secretion capabilities in models mirroring the inhibitory ligand expression found in PRAME (搜索)-expressing tumors. In complex 3-dimensional spheroid tumor models, TK-6302 eliminated multiple rounds of tumors and demonstrated superior anti-tumor activity compared to controls, though the company has not disclosed quantitative benchmarks.
Strategic Target Selection
The choice to target PRAME (搜索) represents an expansion play, as prevalence spans multiple solid tumor histologies with limited treatment options. According to Thomas M. Soloway, President and Chief Executive Officer of T-knife, "PRAME is highly prevalent across multiple high unmet-need solid tumor indications, including squamous non-small cell lung, ovarian, endometrial, skin, and triple-negative breast cancers."
This creates a potentially broad addressable market if HLA restrictions and expression thresholds are managed effectively. The design signals a differentiation attempt against first-wave TCR-T programs, several of which have already added CD8 (搜索) co-receptors to enhance class I–restricted targeting in CD4 cells.
Clinical Trial Design and Operational Considerations
The ATLAS trial will bring the operational complexities typical of autologous cell therapy, including apheresis scheduling, lymphodepletion coordination, inpatient-capable monitoring, chain-of-identity custody, and cold-chain logistics. The adaptive framework suggests dose escalation with histology- or biomarker-driven expansions, which can speed signal detection but complicate data operations and manufacturing slotting.
Biomarker operations will be pivotal, with centralized PRAME (搜索) testing and HLA typing potentially affecting screening timelines and enrollment velocity. The non-viral editing process could reduce vector-related bottlenecks and potentially compress vein-to-vein time, though regulators will scrutinize off-target editing, clonality, and release testing rigor.
Regulatory and Competitive Landscape
Under the EU Clinical Trials Regulation, multi-country activation may be more predictable, yet gene-editing products face heightened genomic safety review and long-term follow-up requirements. The company operates in a crowded PRAME (搜索) arena where sponsors are testing both autologous TCR-T cells and TCR-based bispecifics.
Dr. Peggy Sotiropoulou, Chief Scientific Officer of T-knife, emphasized the therapy's potential: "By bolstering T-cell fitness and persistence while overcoming challenging tumor mediated immune barriers, TK-6302 (搜索) has the potential to deliver meaningful clinical benefit, including deep, durable responses across a range of solid tumor cancers."
The FAS (搜索) pathway remodeling represents a notable approach that directly tackles a known resistance mechanism in solid tumors (搜索), though it heightens the need to de-risk unintended tissue effects and apoptosis pathway perturbations. Key near-term milestones include first-patient-in timing, vein-to-vein turnaround times, and early safety outputs including CRS and neurotoxicity rates, persistence kinetics, and dose-limiting toxicities.